An Open-Label Functionality, Safety and Efficacy Study in Patients Undergoing Elective Unilateral Knee Replacement
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
This study is being performed to evaluate the functionality of a device (Sufentanil NanoTab®
PCA System) that has been developed for use by patients to self-administer the ARX-F01 pain
medication (Sufentanil NanoTab 15 mcg) for the treatment of post-operative pain after
undergoing knee replacement surgery.
Another goal of this study is to assess the safety and effectiveness of this non-invasive,
sublingual route of administration of ARX-F01 in decreasing the amount of pain that a patient
experiences following knee replacement surgery.